News & Updates
Filter by Specialty:
Investigative drug for ulcerative colitis passes muster in early trial
25 Jan 2022
The orally administered, small molecule, gut-targeted stabiliser of hypoxia-inducible factor-1α (HIF-1α) GB004 appears to improve disease activity in patients with ulcerative colitis, with the drug being well-tolerated, according to the results of a phase Ib trial.
Investigative drug for ulcerative colitis passes muster in early trial
25 Jan 2022Can digital health revolutionize IBD management?
13 Jan 2022
byStephen Padilla
Digital health technologies (DHTs) can help lower healthcare utilization and costs but appear to have not enough juice to reduce the risk of relapse, improve quality of life (QoL), and increase treatment adherence in patients with inflammatory bowel disease (IBD), according to a study.